Autobahn Therapeutics completes $100 million Series C financing led by Newpath Partners to advance novel therapeutics for depression and other CNS disorders.
Amount Raised
$100 Million
Round Type
Series C
San DiegoBiotechnologyHealth CareTherapeuticsInvestors
Description
Autobahn Therapeutics, a biotechnology company, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners, with participation from new investors Canaan Partners, Monograph Capital, and Insight Partners, as well as existing investors.
Quick answer
Autobahn Therapeutics raised $100 Million in a Series C round, dated July 24, 2024. Investors: Gt Healthcare Capital Partners, Alexandria Venture Investments, Section 32, Pfizer Ventures, Bristol Myers Squibb, Biogen, Samsara Bio Capital and Invus. Autobahn Therapeutics is based in San Diego, California, United States.
- How much did Autobahn Therapeutics raise?
- Autobahn Therapeutics raised $100 Million in a Series C round on July 24, 2024.
- Who invested in Autobahn Therapeutics?
- Gt Healthcare Capital Partners, Alexandria Venture Investments, Section 32, Pfizer Ventures, Bristol Myers Squibb, Biogen, Samsara Bio Capital and Invus are named as investors in this round.
- What does Autobahn Therapeutics do?
- Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders.
- Where is Autobahn Therapeutics based and how big is it?
- Autobahn Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Autobahn Therapeutics?
- Fundz holds 1 contact at Autobahn Therapeutics, including the Senior Director - Translational Neuroscience. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Autobahn Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- HDAX Therapeutics raised $3.2M (Seed) on September 5, 2024.
- TippingPoint Biosciences raised an undisclosed amount (Pre-Seed) on September 5, 2024.
- Arsenal Biosciences raised $325M (Series C) on September 4, 2024.
- Cumulus Oncology raised $50M (Series A) on September 3, 2024.
- Navigator Medicines raised $100M (Series A) on August 27, 2024.
- Radiant raised $34M on August 27, 2024.
Who to call at Autobahn Therapeutics, and when
A new round usually means Autobahn Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Autobahn Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Autobahn Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Autobahn Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Autobahn Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Autobahn Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.